5-Amino-1MQ (50 mg Vial) Dosage Protocol

Quickstart Highlights

5-Amino-1MQ dosing protocols focus on this selective, cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), which has been studied for its potential role in supporting fat metabolism, maintaining lean muscle mass, and increasing intracellular NAD⁺ levels. Through inhibition of NNMT, 5-Amino-1MQ may contribute to restoration of cellular energy balance and activation of SIRT1 pathways associated with metabolic efficiency. This educational protocol outlines a subcutaneous injection strategy intended to optimize bioavailability when using the 50 mg vial format.

Reconstitute: Add 4.0 mL bacteriostatic water → 12.5 mg/mL concentration.
Typical daily range: 2.5–5 mg once or twice daily (subcutaneous).
Easy measuring: At 12.5 mg/mL, 1 unit = 0.01 mL = 0.125 mg (125 mcg) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Subcutaneous Protocol (4 mL = 12.5 mg/mL)

Phase	Daily Dose (mg)	Units (per injection) (mL)
Days 1–2 (Tolerance)	2.5 mg once daily	20 units (0.20 mL)
Days 3+ (Standard)	5 mg once daily	40 units (0.40 mL)
Alternative BID	2.5 mg twice daily	20 units (0.20 mL) × 2

Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 50 mg vial provides 10–20 days of research material at these doses.

Reconstitution Steps

Remove the vial from frozen storage (−20 °C / −4 °F) and allow it to equilibrate at room temperature for approximately 15–20 minutes.
Using a sterile syringe, withdraw 4.0 mL of bacteriostatic water.
Introduce the diluent slowly along the inner wall of the vial to minimize foaming.
Gently swirl or roll the vial until the contents are fully dissolved; the solution should appear clear. Do not shake.
Label the vial and store refrigerated at 2–8 °C (35.6–46.4 °F), protected from light, and use within 2–4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption

Supplies Needed

Plan based on research duration using the 50 mg vial format at 5 mg/day.

5-Amino-1MQ Vials (50 mg each):
- 1 week (5 mg/day) ≈ 1 vial
- 2 weeks (5 mg/day) ≈ 1 vial
- 4 weeks (5 mg/day) ≈ 2 vials
Insulin Syringes (U-100):
- Per week (once daily): 7 syringes
- Per week (BID): 14 syringes
- 4 weeks (once daily): 28 syringes
Bacteriostatic Water (10 mL bottles): Use 4.0 mL per vial for reconstitution.
- 1 week (1 vial): 4 mL → 1 × 10 mL bottle
- 2 weeks (1 vial): 4 mL → 1 × 10 mL bottle
- 4 weeks (2 vials): 8 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- Per week (once daily): 14 swabs
- 4 weeks (once daily): 56 swabs → recommend 1 × 100-count box

Protocol Overview

Concise summary of the subcutaneous regimen.

Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels.
Schedule: Daily subcutaneous injections; each 50 mg vial provides 10–20 days of research material.
Dose Range: 2.5–5 mg once or twice daily.
Reconstitution: 4.0 mL per 50 mg vial (12.5 mg/mL) for accurate measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

Dosing Protocol

Suggested approach for the 50 mg vial format.

- Start: 2.5 mg once daily to assess tolerance.
- Target: 5 mg once daily or 2.5 mg twice daily (BID).
- Frequency: Once or twice per day (subcutaneous).
- Vial Duration: Single 50 mg vial lasts 10–20 days at research doses.
- Timing: Morning administration preferred; BID dosing may be split AM/PM.

Storage Instructions

Proper storage preserves compound stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
Do not refreeze reconstituted solution.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each administration; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
Document daily dose and site rotation to maintain consistency.
The 50 mg vial format is ideal for extended research cycles; a single vial can last 10–20 days.

How This Works

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small-molecule compound that selectively inhibits nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that catalyzes the methylation of nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In conditions such as obesity and metabolic dysfunction, NNMT is frequently overexpressed in adipose tissue, leading to depletion of nicotinamide and a reduction in NAD⁺ availability.

By inhibiting NNMT activity, 5-Amino-1MQ may preserve nicotinamide for NAD⁺ synthesis, thereby supporting activation of SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation. Preclinical research suggests that NNMT knockdown or pharmacologic inhibition can protect against diet-induced weight gain and improve metabolic parameters without decreasing food intake.

Potential Benefits & Side Effects

Observations drawn from preclinical and early-stage research literature.

May support reductions in fat mass while preserving lean muscle tissue in animal models.
Associated with increased NAD⁺ levels and activation of SIRT1 pathways in preclinical studies.
Enhanced grip strength has been observed in aged mice when combined with exercise.
Generally well tolerated, with occasional reports of mild headache, transient jitteriness, or localized injection-site reactions.
Long-term human safety data have not been established; this compound remains investigational.

Lifestyle Factors

Supportive approaches intended to complement overall outcomes.

Pair with a balanced, protein-forward dietary pattern tailored to individual energy needs.
Combine resistance training with aerobic activity; preclinical evidence suggests potential synergy with exercise.
Prioritize sufficient sleep and effective stress management to support metabolic adaptation.
Consider complementary NAD⁺ precursor compounds (such as NMN or NR) in accordance with emerging stack-based protocols.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
Slow injection may minimize any stinging sensation associated with the compound.

Recommended Source

We recommend Ion Peptide for high-purity 5-Amino-1MQ (50 mg).

Why Ion Peptide?

High-purity (≥99% HPLC), third-party-tested lots with batch COAs.
Consistent, ISO-aligned handling and documentation.
Reliable fulfillment to maintain cold-chain integrity.

Shop at Ion Peptide

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.